Recent studies have shown that Vorinostat and Butyrate (targeting HDAC1, 2, 3, 8) can significantly increase the expression levels of β2M and HLA-class I in various Colorectal Cancer-Cancer Initiating Cells (CRC-CICs). The gene discussed is HDAC1; the disease is colorectal cancer.